RIFBAR: Combining E-cigarette with Innovative Gaming Experience

2Firsts Events by 2FIRSTS
Sep.07.2024
RIFBAR: Combining E-cigarette with Innovative Gaming Experience
RIFBAR attracts attention at e-cigarette expo in Malaysia, showcasing innovative products with gaming integration for social interaction.

At the e-cigarette exhibition in Malaysia, the RIFBAR booth attracted numerous onlookers. On the morning of September 7, Ray, the head of sales department at RIFBAR, was interviewed by 2Firsts. He stated that choosing to showcase their products in the core area of the exhibition was a strategic market exploration. "Our products are creative and unique. We wanted to test the Malaysian market and evaluate the potential of RIFBAR products in Malaysia."

 

Merge the game with e-cigarettes

 

As an emerging e-cigarette brand, RIFBAR has established influence in the markets of the United States and Europe. The highlight of its products is the built-in gaming function, allowing users to interact with games on the screen while using the e-cigarette. Users can even "connect" two e-cigarette devices and socialize with others. This creative design that combines e-cigarettes with gaming interaction has given RIFBAR a unique positioning in the competitive market.

 

Our core belief is to encourage more social interaction through our products," explained Ray. "We aim to bring diverse fun and social elements to users.

 

RIFBAR: Combining E-cigarette with Innovative Gaming Experience
Exhibition items at RIFBAR | Image source: 2Firsts

 

International expansion and regional layout

 

Ray explained that the company currently has offices in several countries, including the United States, Ukraine, the United Arab Emirates, and China, and plans to further expand into global markets. In particular, RIFBAR has established a team of 75 employees in Ukraine and 13 employees in China to support expansion into the Asia-Pacific market.

 

Currently, the main focus of RIFBAR in the market is on the United States. In the US, RIFBAR's TurboX Pro is the brand's best-selling product, and Ray is confident in this. He stated that this product combines creativity and technology, and has received positive feedback from consumers due to its innovative gaming features and practical design.

 

RIFBAR: Combining E-cigarette with Innovative Gaming Experience
RIFBAR Sales Department Manager Ray | Image source: 2Firsts

 

Testing the waters of the Malaysian market

 

When asked about the reason for participating in the Malaysia exhibition, Ray openly admitted that RIFBAR hopes to use this opportunity to test the market and understand the reaction of Malaysian consumers to their innovative products. "We want to see if we can find a breakthrough here through this exhibition and showcase the uniqueness of our products," Ray added. With creative design and social features, RIFBAR believes that they are more innovative and unique compared to other brands in the market.

 

Ray stated that although the e-cigarette market is competitive, RIFBAR's products stand out with a unique positioning that caters to consumers seeking novel experiences. He emphasized that RIFBAR aims to inject more vitality into the e-cigarette industry through continuous innovation.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
The U.S. Food and Drug Administration has revised the rules under Import Alert 98-07 to incorporate its May 2026 enforcement-priority policy for certain electronic nicotine delivery systems marketed without premarket authorization. The alert continues to allow detention without physical examination, or DWPE, for ENDS lacking required marketing authorization, while directing field divisions to apply the May risk-based framework. When necessary, detention or refusal decisions must also undergo review by the FDA's Center for Tobacco Products. Products including PACHA and Vuse Pro have already emerged as industry examples of the May policy, although enforcement discretion does not constitute FDA marketing authorization.
News
Sep.28 by 2Firsts Perspectives
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
The U.S. Department of Health and Human Services has named Bret Koplow permanent director of the FDA’s Center for Tobacco Products, ending his period as acting chief. Koplow has spent years working on tobacco regulation, law and policy inside the FDA and, while serving as acting director, pushed for faster PMTA reviews and nicotine pouch review pilots. HHS also said CTP will prioritize innovation and access to less harmful alternatives for adult smokers while continuing efforts to protect youth.
Sep.09
China’s Jiangsu Tobacco Monopoly Bureau and Drug Regulator Target Illegal Vape Sales Disguised as Medical Devices, Define Six Violations
China’s Jiangsu Tobacco Monopoly Bureau and Drug Regulator Target Illegal Vape Sales Disguised as Medical Devices, Define Six Violations
China’s Jiangsu Tobacco Monopoly Bureau and Jiangsu Provincial Medical Products Administration have issued a joint notice targeting illegal production and sales of vape products disguised as medical devices. The notice identifies six categories of violations, including obtaining medical licenses through false materials, misusing medical device credentials, expanding production beyond approved scopes, and using medical device-related online platforms to promote or sell vape products. The action is based on China’s tobacco and medical device regulations and aims to strengthen vape oversight and consumer protection.
Aug.04
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
2Firsts reviewed the original federal court complaint filed by Altria subsidiaries Helix Innovations and NJOY on Sept. 2 challenging FDA’s 2021 PMTA rule. The lawsuit questions whether FDA’s review process complies with the Tobacco Control Act’s 180-day timeline, even as the agency moves to accelerate PMTA reviews and issues more marketing orders. Drawing on the complaint, FDA records, government audits and recent court rulings, 2Firsts examines the legal arguments, supporting evidence and potential implications for the U.S. tobacco review system.
Regulations
Sep.03
From a 2017 Launch to 48% of South Korea’s Heated Tobacco Market, KT&G Looks Back on a Decade of lil
From a 2017 Launch to 48% of South Korea’s Heated Tobacco Market, KT&G Looks Back on a Decade of lil
KT&G announced on Aug. 13, 2026, that it has opened “lil Archive,” a brand exhibition space in Seoul showcasing the evolution, technology platforms and future direction of its heated tobacco brand lil since its launch in 2017. KT&G said lil now spans three major platforms — lil SOLID, lil HYBRID and lil AIBLE — with more than 30 dedicated consumables, and held a 48% share of South Korea's heated tobacco market in the second quarter of 2026. The opening comes as lil enters its 10th year, with KT&G continuing to position the brand for expansion beyond its domestic market.
Aug.14
Product | R.J. Reynolds Launches Four Flavored Vuse Pro Pods for Vuse Alto Devices in U.S.
Product | R.J. Reynolds Launches Four Flavored Vuse Pro Pods for Vuse Alto Devices in U.S.
R.J. Reynolds Vapor Company has introduced Vuse Pro prefilled pods in Peach, Berry, Watermelon and Fresh Mint in selected U.S. states. Vuse’s U.S. website says the pods are intended for use with existing Vuse Alto devices. Each contains 2.0 mL of e-liquid at 5.0% nicotine by weight, uses nicotine salts and is offered in two- and four-pod packs. Reynolds said the rollout includes mandatory ID scanning for every purchase, purchase limits, stronger retailer-accountability requirements and strict age-restricted marketing standards. The four pods have not received marketing authorization from the U.S. Food and Drug Administration.
Sep.10